Effect of dapsone on survival in HIV-infected patients: A meta-analysis;Effet de la dapsone sur la survie des patients infectes par le VIH: Une meta-analyse des essais termines

Revue d'Epidemiologie et de Sante Publique

Volumn 48, Issue 1, 2000, Pages 17-30

  Saillour Glenisson F ^a   Chene G ^a   Salmi, L R ^a   Hafner, R ^b   Salamon, R ^a  

^a INSERM   (France)

^b NONE

Author keywords

Dapsone; HIV; Meta analysis; Survival

Indexed keywords

DAPSONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; SURVIVAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS; DAPSONE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; PNEUMONIA, PNEUMOCYSTIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0343673761     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Munoz A, Schrager LK, Bacellar H et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991. Am J Epidemiol 1993; 137: 423-38.
2. Delmas MC, Schwoebel V, Heisterkamp SH, Downs AM. Ancelle-Park RA, Brunet JB. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. J Acquir Immune Defic Syndr 1995; 9: 74-80.
3. Hoover DR. The effects of long term Zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature. Drugs 1995; 49: 20-36.
4. Chan ISF, Neaton JD, Saravolatz LD, Crane LR, Osterberger J for the Community Programs for Clinical Research on AIDS. Frequencies of opportunistic disease prior to death among HIV-infected persons. AIDS 1995; 9: 1145-51.
5. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines. JAMA 1997; 278: 337-8.
6. Medina I, Mills J, Leoung GS et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprimdapsone. N Engl J Med 1990; 323: 776-82.
7. Mallolas J, Zamora L, Gatell JM et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993; 7: 59-64.
8. Bozzette SA, Finkelstein DM, Spector SA et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693-9.
9. Girard PM, Landman R, Gaudebout C et al. Dapsonepyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993; 328: 1514-20.
10. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1992; 5: 341-7.
11. Torres RA, Thorn M Barr M et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993; 95: 573-83.
12. Opravil M, Hirschel B, Lazzarin A et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Inject Dis 1995; 20: 531-41.
13. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Ron Lucas C. Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992; 6: 1169-74.
14. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156: 177-88.
15. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii Pneumonia and Toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 104-14.
16. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infec Dis 1998; 27: 191-204.
17. Salmon-Ceron D, Fontbonne A, Saba J et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995; 172: 656-64.
18. Antinori A, Murri R, Tamburrini E, De Luca A. Ortona L. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia (letter). Lancet 1992; 340: 788.
19. Antinori A, Murri R, Ammassari A et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995; 9: 1343-50.
20. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews using updated individual patients data). Stat Med 1995; 14: 2057-79.
21. Chalmers TC, Smith HJR, Blackburn B et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981; 2: 31-49.
22. Hedges LV, Olkin I. Statistical methods for meta-analysis. London: Academic press. 369 p.
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88.
25. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-94.
26. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
27. Collett D. Modelling survival data in medical research. Chapman &Hall, London, 1994, 347 p.
28. Podzamczer D, Santin M, Jimenez J, Casanova A, Bolao F, Gudiol GRK. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993; 7: 501-6.
29. Sirera G, Clotet B, Romeu J, Raventos A, Gomez N, Paredes R. A randomized study of primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and cerebral toxoplasmosis (CT) with twice weekly dapsone-pyrimethamine versus thrice weekly Co-trimoxazole. II National Conference on Human Retroviruses. Washington, USA, 1995. Abstract 295.
30. Grünewald Th, Bergmann F, Eljaschewitsch J, Pohle HD, Ruf B. Antiprotozoal prophylaxis in AIDS patients - results of a prospective randomized study comparing dapsone/pyrimethamine and sulfadoxine/ pyrimethamine. IX International Conference on AIDS. Berlin, Germany, 1993. Abstract WS-B13-3.
31. Podzamczer D, Salazar A, Jimenez J et al. Intermittent Trimethoprim-sulfametrioxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122: 755-61.
32. Zamora L, Mallolas J, Miro JM et al. Primary prophylaxis of toxoplasmic encephalitis (TE) and P Carinii Pneumonia (PCP) in HIV patients. XXXV Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, 1995. Abstract 1224.
33. Cruciani M, Concia Z, Adami T et al. Trimethoprim-Sufamethoxazole versus dapsone for PCP prophylaxis: preliminary results. II European Conference on AIDS. Paris, France, 1992. Abstract P99.
34. Payen MC, De Wit S, Sommereijns B, Clumeck N. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of pneumocystis carinii pneumonia and toxoplasmosis in patients with aids. Biomed Pharmacother 1997; 51: 439-45.
35. Antinori A, Murri R, Ammassari A et al. A randomized trial of cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of P. Carinii Pneumonia (PCP) and toxoplasmic encephalitis (TE). V European Conference on Clinical Aspects and Treatment of HIV infection. Copenhaguen, Denmark, 1995. Abstract 6.
36. Tocchetti A, Tambini R, Allegro A, Longoni E, Rinaldi E. Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. AIDS 1994; 8: 272-4.
37. Thompson SG, Pocock SJ. Can meta-analysis be trusted? Lancet 1991; 338: 1127-30.
38. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141-51.
39. Cook DJ, Guyatt GH, Ryan G et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993; 269: 2749-53.
40. Chalmers I, Dickersin K, Thomas TC. Getting to grips with Archie Cochrane's agenda. All randomised controlled trials should be registered and reported. Br Med J 1992; 305: 786-7.
41. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 45-57.
42. Vage C, Saab N, Woster PM, Svenson CK. Dapsone-induced hematologic toxicity: comparison of the methaemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Toxicol Appl Pharmacol 1994; 129: 309-16.
43. Duval X, Clayette P, Dereuddre-Bosquet N et al. Dapsone and HIV-1 replication in primary cultures of lymphocytes and monocyte-derived macrophages. AIDS 1997; 11: 943-4.
44. Halliwell B, Cross CE. Reactive oxygen species, antioxidants, and acquired immunodeficiency syndrome. Sense or speculation? Arch Intern Med 1991; 151: 29-31.
45. Lee BL, Safrin S, Makrides V. Gambertoglio JG. Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1996; 40: 1231-6.
46. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996; 5: 36-46.